Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to Genotropin: Somatropin

somatropin, recombinant

Genotropin, Humatrope, Norditropin, Nutropin AQ, Nutropin AQ Pen, Nutropin Depot, Omnitrope, Saizen, Serostim, Tev-Tropin, Zomacton (UK), Zorbtive

Pharmacologic class: Posterior pituitary hormone

Therapeutic class: Growth hormone (GH)

Pregnancy risk category B (Genotropin, Saizen, Serostim), C


Stimulates linear and skeletal growth, increases number and size of muscle cells, and influences internal organ size


Genotropin injection: 1.5 mg (about 4 international units/vial), 5.8 mg (about 15 international units/vial), 13.8 mg (about 41.4 international units/vial)

Humatrope injection: 2 mg (about 6 international units/vial), 5 mg (about 15 international units/vial), 6 mg (about 18 international units/vial), 12 mg (about 36 international units/vial), 24 mg (about 72 international units/vial)

Norditropin injection: 4 mg (12 international units/vial), 8 mg (24 international units/vial)

Norditropin injection cartridge: 5 mg/1.5 ml, 10 mg/1.5 ml, 15 mg/1.5 ml

Nutropin AQ injection: 10 mg

Nutropin AQ Pen injection cartridge: 10 mg

Nutropin Depot: 13.5-mg, 18-mg, and 22.5-mg single-use vials; 13.5-mg, 18-mg, and 22.5-mg kits

Nutropin injection: 5 mg (about 15 international units/vial), 10 mg (about 30 international units/vial)

Saizem injection: 5 g (about 15 international units/vial)

Serostim injection: 5 mg (about 15 international units/vial), 6 mg (about 18 international units/vial)

Tev-Tropin injection: 5 mg

Zorbtive injection: 8.8 mg in 10-ml vial

Indications and dosages

Growth failure in children with inadequate endogenous GH

Children: 0.16 to 0.24 mg/kg (Genotropin) subcutaneously q week in six or seven divided doses. Or 0.18 mg/kg/week (Humatrope) subcutaneously or I.M., divided equally and given on three alternate days six times weekly (or daily, if epiphyseal closure hasn't occurred). Or 0.024 to 0.034 mg/kg (Norditropin) subcutaneously six or seven times each week using NordiPen injection pen. Or 0.3 mg/kg/week (Nutropin AQ, Nutropin AQ Pen, Tev-Tropin) subcutaneously in equally divided daily doses. Or 0.06 mg/kg (Saizen) subcutaneously or I.M. three times weekly.

Endogenous GH replacement in adults with GH deficiency

Adults: 0.04 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses. Or 0.006 mg/kg/day (Humatrope) subcutaneously. Or initially, no more than 0.006 mg/kg/day (Nutropin AQ, Nutropin AQ Pen, Tev-Tropin) subcutaneously; may increase to a maximum of 0.025 mg/kg daily in patients younger than age 35 or 0.0125 mg/kg/day in patients ages 35 and older. Or 0.005 mg/kg/day (Saizen) subcutaneously; may increase to a maximum of 0.01 mg/kg/day after 4 weeks, depending on patient tolerance.

Short stature related to Turner's syndrome

Children: 0.375 mg/kg/week (Humatrope) subcutaneously, divided into equal doses given on 3 alternate days or daily. Or up to 0.375 mg/kg/week (Nutropin AQ, Nutropin AQ Pen) subcutaneously, divided into equal doses given three or seven times weekly.

Idiopathic short stature (non-GH-deficient) in children whose epiphyses haven't closed

Children: Up to 0.37 mg/kg (Humatrope) subcutaneously q week. Divide dosage and give in equal doses six or seven times weekly.

Growth failure in children with Prader-Willi syndrome

Children: 0.24 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses

Infants born small for gestational age

Children: 0.48 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses

AIDS wasting or cachexia

Adults and children weighing more than 55 kg (121 lb): 6 mg (Serostim) subcutaneously at bedtime

Adults and children weighing 45 to 55 kg (99 to 121 lb): 5 mg (Serostim) subcutaneously at bedtime

Adults and children weighing 35 to 45 kg (77 to 99 lb): 4 mg (Serostim) subcutaneously at bedtime

Adults and children weighing less than 35 kg (77 lb): 0.1 mg/kg/day (Serostim) subcutaneously at bedtime

Growth failure due to chronic renal insufficiency (up to time of kidney transplantation)

Children: Up to 0.35 mg/kg/weekly (Nutropin AQ, Nutropin AQ Pen) subcutaneously, divided into daily doses

Short bowel syndrome in patients receiving specialized nutritional support

Adults: 0.1 mg/kg/day subcutaneously (Zorbtive), to a maximum of 8 mg/day for no more than 4 weeks


• Hypersensitivity to drug, benzyl alcohol, glycerin, or metacresol (with some diluents)

• Active neoplasia

• Acute, critical illness after open-heart surgery, acute respiratory failure, or multiple trauma

• Children with closed epiphyses

• Neonates (Zorbtive)


Use cautiously in:

• hypothyroidism

• diabetes mellitus.


• Reconstitute by injecting supplied diluent through rubber top of vial and aiming liquid stream at side of vial. Swirl vial gently to mix; don't shake.

• Inspect reconstituted solution. Don't use if it has visible particles or is cloudy.

• Keep diluted drug refrigerated; use within 14 days.

• When using prefilled cartridges, follow manufacturer's instructions carefully.

• Know that patients receiving Zorbtive for short bowel syndrome may receive specialized nutritional support as needed.

Adverse reactions

CNS: headache, weakness

CV: mild and transient edema

GU: hypercalciuria

Hematologic: leukemia

Metabolic: fluid retention, mild hyperglycemia, hypothyroidism, ketosis

Musculoskeletal: localized muscle pain, tissue swelling, joint pain

Skin: rash, urticaria

Other: pain, inflammation at injection site


Drug-drug. Androgens, thyroid hormone: epiphyseal closure

Corticotrophin, corticosteroids: inhibited growth response (with long-term use)

Drug-diagnostic tests. Alkaline phosphatase, glucose, inorganic phosphorus, parathyroid hormone: increased levels

Patient monitoring

• Monitor patient's height, X-rays, blood chemistry results, blood glucose level, and thyroid function studies.

Watch for signs and symptoms of leukemia.

Patient teaching

• Advise patient and parents that regular check-ups and blood tests are needed to detect adverse reactions.

• Teach parents how to reconstitute and administer drug. Stress importance of following manufacturer's instructions carefully when using prefilled cartridges.

• Teach parents about proper handling and disposal of syringes, needles, and cartridges.

• As appropriate, review all significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

somatropin (recombinant)

(soe-ma-troe-pin) ,


(trade name)


Therapeutic: hormones
Pharmacologic: growth hormones
Pregnancy Category: C


Growth failure in children due to Prader-Willi syndrome.Growth failure in children due to deficiency of growth hormone.Growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2.Short stature associated with Turner syndrome.Idiopathic short stature in children.Growth hormone deficiency in adults as a result of pituitary disease, hypothalamic disease, surgery, radiation or trauma.


Produce growth (skeletal and cellular).
Metabolic actions include:
  • Increased protein synthesis,
  • Increased carbohydrate metabolism,
  • Lipid mobilization,
  • Retention of sodium, phosphorus, and potassium.
Somatropin has the same amino acid sequence as naturally occurring growth hormone and is produced by recombinant DNA techniques.
Growth hormone enhances GI tract mucosal transport of water, electrolytes and nutrients.

Therapeutic effects

Increased skeletal growth in children with growth hormone deficiency.
Replacement of somatropin in deficient adults.
Increased bone density in adult growth hormone–deficient patients.


Absorption: Well absorbed (80%).
Distribution: Localize to highly perfused organs (liver, kidneys).
Metabolism and Excretion: Broken down in renal cells to amino acids that are recirculated; some liver metabolism.
Half-life: Subcut—3.8 hr.

Time/action profile (growth)

IM, subcutwithin 3 mounknown12–48 hr


Contraindicated in: Closure of epiphyses; Active neoplasia; Hypersensitivity to growth hormone orm-cresol preservative; Acute critical illness (therapy should not be initiated) or respiratory failure; Diabetic retinopathy; Prader-Willi syndrome with obesity and respiratory impairment (risk of fatal complications; can be used only if growth hormone deficiency is documented).
Use Cautiously in: Growth hormone deficiency due to intracranial lesion; Coexisting adrenocorticotropic hormone (ACTH) deficiency; Diabetes (may cause insulin resistance); Thyroid dysfunction; Pediatric: Girls with Turner syndrome may be at ↑ risk for pancreatitis; Geriatric: ↑ sensitivity, ↑ risk of adverse reactions; Obstetric / Lactation: Safety not established.

Adverse Reactions/Side Effects


  • edema of the hands and feet


  • hyperglycemia
  • hypothyroidism
  • insulin resistance


  • pancreatitis (life-threatening)


  • pain at injection site
  • local lipoatrophy or lipodystrophy with subcutaneous use


  • arthralgia


Drug-Drug interaction

Excessive corticosteroid use (equivalent to 10–15 mg/m2/day) may ↓ response to growth hormone.


Subcutaneous (Children) Growth hormone inadequacy–0.16–0.24 mg/kg/wk divided in 6–7 daily doses. Prader-Willi syndrome—0.24 mg/kg/wk divided into 6–7 daily doses.Children SGA at birth—0.48 mg/kg/wk divided into 6–7 daily doses.Turner syndrome—0.33 mg/kg/wk divided into 6–7 daily doses. Idiopathic short stature—0.47 mg/kg/wk divided into 6–7 daily doses.
Subcutaneous (Adults) 0.04mg/kg/wk initially divided in 6–7 daily doses or 0.2 mg/day starting dose (without consideration of body weight) then gradually ↑ by 0.1–0.2 mg/day q 1–2 months until clinical response achieved (max dose 0.08 mg/kg/wk).


Powder for injection: 1.5-mg intra-mix cartridge (delivers 1.3 mg), 5.8-mg intra-mix cartridge (delivers 5 mg), 5.8-mg intra-mix cartridge (delivers 5 mg) as Pen 5 system, 13.8-mg intra-mix cartridge (delivers 12 mg), 13.8-mg intra-mix cartridge (delivers 12 mg) as Pen 12 system, MiniQuick system 0.2 mg, MiniQuick system 0.4 mg, MiniQuick system 0.6 mg, MiniQuick system 0.8 mg, MiniQuick system 1 mg, MiniQuick system 1.2 mg, MiniQuick system 1.4 mg, MiniQuick system 1.6 mg, MiniQuick system 1.8 mg, MiniQuick system 2 mg

Nursing implications

Nursing assessment

  • Growth Failure: Monitor bone age annually and growth rate determinations, height, and weight every 3–6 mo during therapy.
  • Lab Test Considerations: Monitor thyroid function prior to and during therapy. May decrease T4, radioactive iodine uptake, and thyroxine-binding capacity. Hypothyroidism necessitates concurrent thyroid replacement for growth hormone to be effective. Serum inorganic phosphorus, alkaline phosphatase, and parathyroid hormone may ↑ with somatropin therapy.
    • Monitor blood glucose periodically during therapy. Diabetic patients may require ↑ insulin dose.
    • Monitor for development of neutralizing antibodies if growth rate does not exceed 2.5 cm/6 mo.
    • Monitor alkaline phosphatase closely in patients with adult growth hormone deficiency.

Potential Nursing Diagnoses

Disturbed body image (Indications)


  • Rotate injection sites with each injection.
    • Genotropin intra-mix: Dissolve powder with solution provided with 2-chamber cartridge as directed. Gently tip cartridge upside down a few times until contents are completely dissolved. Do not shake; shaking can denature the active ingredient. The 1.5-mg cartridge is stable following dilution for 24 hr if refrigerated. The 5.8-mg and 13.8-mg cartridges contain preservatives and are stable for 14 days if refrigerated.
    • Genotropin Pen: Prepare and administer as directed in patient instruction insert. Store in the refrigerator.
    • Genotropin MiniQuick: For single use only. Inject immediately after reconstitution; may be refrigerated for 24 hr after reconstitution. Follow directions on patient package insert for reconstitution and administration.
  • Subcutaneous: Injection volume should not exceed 1 mL.

Patient/Family Teaching

  • Instruct patient and parents on correct procedure for reconstituting medication, site selection, technique for subcut injection, and disposal of needles and syringes. Review dose schedule. Parents should report persistent pain or edema at injection site.
  • Explain rationale for prohibition of use for increasing athletic performance. Administration to persons without growth hormone deficiency or after epiphyseal closure may result in acromegaly (coarsening of facial features; enlarged hands, feet, and internal organs; increased blood glucose; hypertension).
  • Assure parents and child that these dose forms are synthetic and therefore not capable of transmitting Creutzfeldt-Jakob disease, as was the original somatropin, which was extracted from human cadavers.
  • Advise parents to monitor blood glucose closely in children with diabetes mellitus. Parents should also be advised to report persistent severe abdominal pain; may be a symptom of pancreatitis.
  • Emphasize need for regular follow-up with endocrinologist to ensure appropriate growth rate, to evaluate lab work, and to determine bone age by x-ray exam.

Evaluation/Desired Outcomes

  • Child’s attainment of adult height in growth failure secondary to pituitary growth hormone deficiency or idiopathic causes. Therapy is limited to period before closure of epiphyseal plates (approximately up to 14–15 yr in girls, 15–16 yr in boys).
  • Replacement of growth hormone in deficient adults.


A brand name for SOMATOTROPIN.
References in periodicals archive ?
A time-and-motion simulation study found Norditropin pen devices took less total time weekly to use than the comparator Genotropin and Humatrope pen devices, due to differences in time to prepare the device and learn to use (Nickman, Haak, & Kim, 2010).
He pulled out ten vials of Genotropin valued at pounds 2,782.
The biosimilars used to treat GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin.
The recent approval of a follow-on version of Pfizer's Genotropin (recombinant human growth hormone) signalled the beginning of the end of an era in which biopharmaceuticals enjoyed immunity from competition even after expiration of their patent protection.
3,737 2% Prevnar 13 pneumococcal vaccine $3,718 2% Celebrex arthritis $2,719 8% Viagra erectile dysfunction $2,051 4% Norvasc antihypertensive $1,349 -7% Zyvox bacterial infections $1,345 5% Sutent cancer $1,236 4% Premarin menopause $1,073 6% Genotropin HGH deficiency $832 -6% Xalatan glaucoma $806 -36% Benefix hemophilia $775 12% Detrol overactive bladder $761 -14% Vfend fungal infections $754 1% Chantix smoking cessation $670 -7% Pristiq neuropathic pain $630 9% ReFacto AF hemophilia $584 15% Zoloft antidepressant $541 -6% Revatio pulmonary arterial hypertension $534 0% Medrol inflammation $523 3% Alliance Revenues * $3.
It has also been designed to offer significant cost savings compared to the reference product, Genotropin, and other leading recombinant growth hormones.
Pricing strategies: the role of market competition; principal drivers of biogenerics adoption; the pricing strategies of Omnitrope and Genotropin.
In addition, the company has unveiled Genotropin MiniQuick, a growth hormone delivery device containing Genotropin lyophilized powder for long-term replacement therapy in growth hormone deficient (GHD) patients.
Pfizer Discovered and Promptly Reported Subsidiary's Off-Label Marketing of Genotropin to Justice Department, Other Agencies
He identified key products currently in the marketplace as the growth hormone Genotropin, the antithrombotic Fragmin and Xanax for anxiety and panic disorder.
The new plant will be designed to making the manufacturing process for Genotropin more efficient.
Caverject, for erectile dysfunction; Zinecard, which is used in chemotherapy; and Genotropin, a growth hormone, were introduced in the U.